Clinical Data 23andMe study explains variable results with obesity drugs PharmaphorumGene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.Clinical DataMetabolic & GLP-1Read full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaphorum Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: EverSea Medicines to acquire Hasten BiopharmaceuticalsNext: The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun) Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
